{
    "clinical_study": {
        "@rank": "35053", 
        "arm_group": {
            "arm_group_label": "doxotubicin/Genexol-PM", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To evaluate efficacy and toxicity of doxorubicin/Genexol-PM in metastatic breast cancer\n\n        1. Primary Purpose: response rate\n\n        2. Secondary purpose: toxicity, progression-free survival, overall survival"
        }, 
        "brief_title": "A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer", 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or older adult women\n\n          -  Instrumentation measurable lesions with histologically confirmed advanced (recurrent\n             or metastatic) breast cancer\n\n          -  ECOG 0-2\n\n          -  Advanced breast cancer in the past, patients who did not receive chemotherapy\n\n          -  Recurrence if adjuvant chemotherapy and adjuvant chemotherapy in the past for more\n             than 6 months until the patient\n\n          -  life expectancy more than 3 months\n\n          -  Agree in writing before the party to participate in a clinical trial to patients\n\n        Exclusion Criteria:\n\n          -  immunohistochemical staining 3 + or FISH positive anti-HER 2 therapy patients\n\n          -  Severe infections requiring antibiotic therapy\n\n          -  Clinically significant heart disease\n\n          -  Pregnant or lactating woman\n\n          -  Uncontrolled symptoms in the central nervous system (CNS) metastases\n\n          -  Patients diagnosed with malignant tumors of other organs"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01784120", 
            "org_study_id": "2011-GIRBA-2566"
        }, 
        "intervention": {
            "arm_group_label": "doxotubicin/Genexol-PM", 
            "intervention_name": "Doxorubicin/Genexol-PM", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Doxorubicin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "breast cancer", 
            "doxorubicin", 
            "genexol-PM", 
            "paclitaxel"
        ], 
        "lastchanged_date": "August 19, 2013", 
        "location": {
            "contact": {
                "last_name": "Hee Kyung Ahn", 
                "phone": "+82-32-460-3229"
            }, 
            "facility": {
                "address": {
                    "city": "Incheon", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Gachon University Gil Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer", 
        "other_outcome": [
            {
                "measure": "overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }, 
            {
                "measure": "progression-free-survival", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }
        ], 
        "overall_contact": {
            "email": "hkahn@gilhospital.com", 
            "last_name": "Hee Kyung Ahn", 
            "phone": "+82-32-460-3229"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "response rate", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01784120"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Gachon University Gil Medical Center", 
            "investigator_full_name": "Eun Kyung Cho", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "source": "Gachon University Gil Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gachon University Gil Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}